Education
About Us
Working with TipRanks
Follow Us
Novo Nordisk (DE:NOVA)
FRANKFURT:NOVA
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.73Last Year’s EPS
0.72Same Quarter Last Year
Based on 9 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 05, 2025
|% Change Since: -22.89%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong year for Novo Nordisk with substantial sales and profit growth, expansion in patient reach, and significant advancements in R&D. However, challenges such as increased carbon emissions, supply chain investments, and financial losses were noted.Company Guidance
In the Novo Nordisk earnings call for the full year 2024, the company reported a 26% growth in both sales and operating profit. They are now serving over 45 million patients with diabetes and obesity treatments, a significant increase from the previous year. The call highlighted a 23% rise in total carbon emissions due to expanded production and investments in capital expenditure. The company also increased the representation of women in senior leadership positions to 42%. The U.S. and International Operations showed strong sales growth, with North America Operations growing by 30% and International Operations by 19%. The GLP-1 diabetes product segment saw a 22% increase in sales, while obesity care sales surged by 57%, largely driven by the drug Wegovy. Novo Nordisk's Rare Disease sales also grew by 9%. The company outlined its strategic initiatives in the obesity segment, including advancements in its CagriSema trials and the introduction of semaglutide 7.2 milligram and amycretin. The financial outlook for 2025 anticipates continued growth, with sales expected to rise between 16% and 24%. The call also addressed the impact of the Inflation Reduction Act and outlined future plans for its R&D pipeline and capacity expansions.Strong Financial Performance
Novo Nordisk achieved a 26% sales growth and 26% operating profit growth in 2024, driven by the GLP-1 portfolio. Sales in North America Operations grew by 30% and International Operations by 19%.
Significant Increase in Patient Reach
The company now serves more than 45 million patients with diabetes and obesity treatments, an increase of almost 4 million patients compared to last year.
Expansion in Obesity Care Market
Obesity care sales increased by 57%, driven by North America Operations growing 45% and International Operations growing 107%.
R&D Advancements
Several obesity readouts were achieved, including CagriSema, semaglutide 7.2 mg, and amycretin, reinforcing the strategic aspiration of developing superior treatment solutions.
Catalent Acquisition Completed
The acquisition of Catalent sites was completed, supporting ongoing scaling efforts and expanding Novo Nordisk's global fill and finish footprint from 11 to 14 sites.
---
DE:NOVA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DE:NOVA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 05, 2025 | €78.84 | €80.82 | +2.51% |
| Nov 06, 2024 | €98.41 | €96.43 | -2.01% |
| Aug 07, 2024 | €117.27 | €107.90 | -7.98% |
| May 02, 2024 | €118.25 | €116.77 | -1.25% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Novo Nordisk (DE:NOVA) report earnings?
Novo Nordisk (DE:NOVA) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Novo Nordisk (DE:NOVA) earnings time?
Novo Nordisk (DE:NOVA) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Novo Nordisk stock?
The P/E ratio of Novo Nordisk is N/A.
What is DE:NOVA EPS forecast?
DE:NOVA EPS forecast for the fiscal quarter 2025 (Q1) is 0.73.
---
